Table 1.
Demographic characteristics of the participants in phase 1
|
3–5 years |
6–12 years |
13–17 years |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaccine 2 μg (n=24) | Vaccine 4 μg (n=24) | Vaccine 8 μg (n=24) | Control (n=24) | Vaccine 2 μg (n=24) | Vaccine 4 μg (n=24) | Vaccine 8 μg (n=24) | Control (n=24) | Vaccine 2 μg (n=24) | Vaccine 4 μg (n=24) | Vaccine 8 μg (n=24) | Control (n=24) | |
| Age, years | ||||||||||||
| Mean | 4·6 (0·9) | 4·5 (0·9) | 5·3 (0·7) | 4·7 (0·8) | 9·8 (1·9) | 9·3 (2) | 9·2 (2·1) | 10 (1·6) | 14·7 (1·2) | 15·1 (1·4) | 14·4 (1·1) | 14·9 (1·2) |
| Median | 4·8 (3·7–5·0;3·2–6·0) | 4·6 (3·7–5·3;3·0–5·9) | 5·4 (4·8–5·9;3·8–6·0) | 4·9 (3·9–5·4;3·1–5·8) | 9·8 (8·1–11·6;6·8–13·0) | 9·4 (7·2–10·3;6·3–13·0) | 9·1 (7·0–11·0;6·0–12·5) | 10·4 (9·1–11·1;6·4–12·2) | 14·5 (13·9–15·6;13·2–17·3) | 15·0 (14·3–16·1;13·1–17·8) | 14·2 (13·5–15·1;13·1–16·6) | 14·9 (14·1–15·6;13·2–17·3) |
| Sex | ||||||||||||
| Male | 17 (71%) | 13 (54%) | 11 (46%) | 11 (46%) | 13 (54%) | 14 (58%) | 7 (29%) | 11 (46%) | 12 (50%) | 10 (42%) | 15 (63%) | 17 (71%) |
| Female | 7 (29%) | 11 (46%) | 13 (54%) | 13 (54%) | 11 (46%) | 10 (42%) | 17 (71%) | 13 (54%) | 12 (50%) | 14 (58%) | 9 (37%) | 7 (29%) |
| Ethnicity | ||||||||||||
| Han | 23 (96%) | 24 (100%) | 24 (100%) | 24 (100%) | 23 (96%) | 24 (100%) | 24 (100%) | 23 (96%) | 22 (92%) | 22 (92%) | 23 (96%) | 22 (92%) |
| Hui | 1 (4%) | 0 | 0 | 0 | 1 (4%) | 0 | 0 | 1 (4%) | 1 (4%) | 2 (8%) | 1 (4%) | 1 (4%) |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (4%) | 0 | 0 | 1 (4%) |
Data mean (SD), median (IQR; range), or n (%).